UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Ledermann, JA; Harter, P; Gourley, C; Friedlander, M; Vergote, I; Rustin, G; Scott, C; ... Matulonis, U; + view all (2016) Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer , 115 (11) pp. 1313-1320. 10.1038/bjc.2016.348. Green open access

[img]
Preview
Text
Ledermann_bjc2016348a.pdf - Published version

Download (273kB) | Preview

Abstract

BACKGROUND: Maintenance monotherapy with the poly(ADP-ribose) polymerase inhibitor olaparib significantly prolongs progression-free survival over placebo in patients with platinum-sensitive relapsed serous ovarian cancer, with greatest benefit seen in patients with a BRCA1/2 mutation (BRCAm). Preservation of health-related quality of life (HRQoL) is important during maintenance therapy; we evaluated the effect of olaparib on HRQoL in this Phase II trial (NCT00753545, Study 19). METHODS: Patients received olaparib 400 mg b.i.d. (capsules) or placebo until progression. Patient-reported HRQoL and disease-related symptoms were evaluated using the FACT-Ovarian (FACT-O) questionnaire (completed at baseline and every 28 days until progression), the FACT/NCCN Ovarian Symptom Index (FOSI) and the Trial Outcome Index (TOI). TOI of the FACT-O was the primary measure. RESULTS: Overall, 265 women were randomised to maintenance olaparib (n=136) or placebo (n=129). Compliance for HRQoL assessment was high (~80% over time). Most patients in both arms reported a best response of ‘no change’ on TOI (81%) and other HRQoL measures. There were no statistically significant differences in time to worsening or improvement rates of TOI, FOSI and FACT-O scores in the overall, BRCAm and germline BRCAm populations. CONCLUSIONS: Maintenance treatment with olaparib was well tolerated and had no adverse impact on HRQoL in this study of patients with platinum-sensitive relapsed serous ovarian cancer who had responded to their most recent platinum-based therapy (partial or complete response). Interpretation of the HRQoL results in this population may differ from patients who have not responded to their most recent platinum-based therapy.

Type: Article
Title: Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/bjc.2016.348
Publisher version: http://doi.org/10.1038/bjc.2016.348
Language: English
Additional information: © 2016 Cancer Research UK. All rights reserved. This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, olaparib, quality of life, maintenance treatment, ovarian cancer, BRCA, FACT-O questionnaire, PATIENT-REPORTED OUTCOMES, PHASE-III, OPEN-LABEL, CLINICAL-TRIALS, BREAST-CANCER, MULTICENTER, BEVACIZUMAB, AZD2281
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/1529634
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item